Analysis of natural killer‐associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications

Abstract

The aim of this study was to analyse the expression of NK-associated antigens in both peripheral blood and bone marrow lymphocytes from a large series of newly diagnosed multiple myeloma patients. 112 patients with untreated multiple myeloma (MM) were included in the study. 36 sex- and age-matched healthy volunteers were used as controls for peripheral blood (PB) studies and 14 for the bone marrow (BM) studies. Simultaneous stainings with the CD3/CD56, CD2/CD16 and CD8/CD57 monoclonal antibodies were systematically performed in PB and CD3/CD56 and CD2/CD16 in BM in order to analyse their relationship with the clinical and biological characteristics of the disease and survival. The expression of NK-associated antigens (CD56, CD16 and CD57) assessed within the lymphoid gate, was significantly increased (P < 0.001) in the PB of MM patients both in relative and absolute numbers. In the BM a significant increase in the percentage of CD56+ lymphocytes (P < 0.001) was also observed; in contrast, the proportion of CD16+ cells did not differ significantly from that of normal BM samples. The number of CD56+CD3- lymphocytes increased significantly within high-risk patients (869 +/- 671) as compared to intermediate (388 +/- 212) and low-risk patients (274 +/- 199) (P = 0.04). Moreover, patients with high values of CD56+CD3- lymphocytes showed a statistically significant association with several adverse prognostic factors including anaemia, hypoalbuminaemia, renal failure, high beta 2M, DNA diploidy and high S-phase plasma cells. In addition, patients with higher absolute numbers of PB CD56+CD3-lymphocytes displayed a poorer prognosis, whereas patients with higher values of CD57+CD8- cells had a better outcome.

Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry

“…Similarly to what has been previously described for symptomatic MM, 12,[23][24][25] effector CD8 + T and NK cells were also found to be increased in LTDC-MM. Recruitment of cytotoxic cells into the tumor microenvironment could reflect a host immune surveillance mechanism to control tumor growth, which would be inefficient in newly-diagnosed symptomatic patients.…”

Plasma Cell Leukemia: Case Series From a Tertiary Center with Review of Literature

“…Immunophenotypic characterization of peripheral plasma cells was performed as previously described by GraciaSanz et al [13]. Monoclonal antibodies (MoAbs) tested included-CD38, CD5, CD19, CD20, CD23, CD10, CD25, CD103, FMC-7, kappa and lambda light chain.…”

The “ex Vivo” Patterns of CD2/CD7, CD57/CD11c, CD38/CD11b, CD45RA/CD45RO, and CD11a/HLA-DR Expression Identify Acute/Early and Chronic/Late NK-Cell Activation States

“…Increased numbers of circulating NK-cells have been described in various physiological and pathological conditions (1)(2)(3)(4), in addition to NKcell leukemias/lymphomas (5,6). In the former cases, they are believe to represent reactive cells that proliferate in response to a stimulus and that play an important role in host defense by exhibiting cytotoxicity against tumor and virus-infected cells, whereas in the latter case the malignant NK-cell population shows autonomous proliferation (7,8).…”